Subclassification of Hepatocellular Carcinoma with Barcelona Clinic Liver Cancer Intermediate Stage.
10.17998/jlc.2016.16.1.17
- Author:
Hye Won LEE
1
;
Seung Up KIM
;
Jun Yong PARK
;
Do Young KIM
;
Sang Hoon AHN
;
Kwang Hyub HAN
;
Beom Kyung KIM
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. beomkkim@yuhs.ac
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Sub-classification;
Prognosis;
Barcelona Clinic Liver Cancer Stage;
Intermediate
- MeSH:
Carcinoma, Hepatocellular*;
Humans;
Liver Neoplasms*;
Liver*;
Prognosis
- From:Journal of Liver Cancer
2016;16(1):17-22
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) with Barcelona Clinic Liver Cancer (BCLC) intermediate stage includes a highly heterogeneous population. Here, we aimed to sub-classify hepatocellular carcinoma with BCLC intermediate stage for better prognostification. METHODS: Between 2003 and 2008, 325 patients who were newly diagnosed as HCC with BCLC intermediate stage were considered eligible. Tumor factor and liver function were used for sub-classification. Overall survival (OS) was analyzed using Kaplan-Meier method with a comparison by log-rank test. RESULTS: A total of 325 patients with intermediate stage HCC were analyzed. Patients with tumor size ≥7 cm, tumor number ≥4 and Child-Pugh class B had the worse OS compared to those with tumor size <7 cm, tumor number <4 and Child-pugh class A, respectively (all P<0.05). These three variables affected the OS independently from multivariate Cox regression analysis (all P<0.05). So, using these three variables, patients were finally sub-classified as those with fulfilling none of three factors (B-a), one of three factors (B-b), two of three factors (B-c) and all of three factors (B-d) with the median OS of 39.2, 20.6, 12.0 and 8.3 months with statistical significances (all P<0.05 between B-a and B-b, between B-b and B-c, and between B-c and B-d), respectively. CONCLUSIONS: Sub-classification of HCC with BCLC intermediate stage may be useful in not only prognostification but also guidance of treatment strategies.
